載入...
Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986–2019
BACKGROUND: Digoxin immune fab products, DigiBind and DigiFab, are antidotes for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. Although approved by the US Food and Drug Administration (FDA) in 1986 (DigiBind) and 2001 (DigiFab), there r...
Na minha lista:
| 發表在: | Drugs Real World Outcomes |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8128941/ https://ncbi.nlm.nih.gov/pubmed/33721285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40801-021-00242-x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|